http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2568593-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9ce99448ffa2ae8af096396220116bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_375155664ebe04e02d1031458d0bec2b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 |
| filingDate | 2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a5c723cf31a4242a4276bfe7bb6c673 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3513fda48f55fd66cf314dd730828791 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79fd9bb103bea6772e424d7f7fc0bec5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9c49660a99d5beea501a25c57fbf0f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b7505c42634edf697c96d038b6e17a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c8c4300d0a805c944b9e7a02aa98960 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36df495d1eee274976981c7b0cdf4721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dcffa0fdbedf45228772c8f655fbdef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a9fff9cca09d8ca14ecb560008b8b56 |
| publicationDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2568593-C1 |
| titleOfInvention | Method for preventing thrombocytopenia in patients with chronic hepatitis c and receiving combination antiviral therapy |
| abstract | FIELD: medicine. n SUBSTANCE: invention can be used to prevent thrombocytopenia developing in the patients with chronic hepatitis C (CHC) as a result of a combination antiviral therapy (CAT). That is ensured by daily intravenous administrations of autoblood haemolysate (ABH) exactly 10 days before the beginning of the CAT in the CHC patients in need of the CAT; from the beginning and throughout the duration of the CAT course, the ABH intravenous administration continues in the same dose, however every 7 days; the ABH intravenous administration is combined with taking patient's blood 10.0 ml in a syringe 20.0 ml 50% pre-filled with distilled water; thereafter, with a puncture needle kept inserted, autoblood haemolysate produced in the syringe is re-injected into a vascular bed. n EFFECT: method enables reducing a ratio of patients suffering moderate and severe CAT-associated thrombocytopenia. n 1 tbl, 1 ex |
| priorityDate | 2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.